450 related articles for article (PubMed ID: 12942574)
21. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
22. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
23. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
[TBL] [Abstract][Full Text] [Related]
24. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
[TBL] [Abstract][Full Text] [Related]
25. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
26. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Rényi I; Bárdi E; Udvardi E; Kovács G; Bartyik K; Kajtár P; Masát P; Nagy K; Galántai I; Kiss C
Pathol Oncol Res; 2007; 13(1):57-62. PubMed ID: 17387390
[TBL] [Abstract][Full Text] [Related]
27. Tumour lysis syndrome in children: experience of last decade.
Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
[TBL] [Abstract][Full Text] [Related]
28. Managing malignancy-associated hyperuricemia with rasburicase.
Cheson BD; Dutcher BS
J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
[TBL] [Abstract][Full Text] [Related]
29. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
30. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
31. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Zaidi SZ; Aljurf M
J Clin Oncol; 2004 Aug; 22(16):3430-1; author reply 3431-2. PubMed ID: 15310789
[No Abstract] [Full Text] [Related]
32. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
34. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Gopakumar KG; Thankamony P; Seetharam S; P K
Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
[TBL] [Abstract][Full Text] [Related]
35. Rasburicase improves hyperuricemia in infants with acute kidney injury.
Hobbs DJ; Steinke JM; Chung JY; Barletta GM; Bunchman TE
Pediatr Nephrol; 2010 Feb; 25(2):305-9. PubMed ID: 19936796
[TBL] [Abstract][Full Text] [Related]
36. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Reeves DJ; Bestul DJ
Pharmacotherapy; 2008 Jun; 28(6):685-90. PubMed ID: 18503395
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
39. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC; Pui CH
Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
[TBL] [Abstract][Full Text] [Related]
40. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]